{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:51Z","timestamp":1775570751520,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04690-3","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:53:19Z","timestamp":1772445199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["OCT-based morphological prognostic factors for structural improvement after anti-VEGF therapy in wet age-related macular degeneration"],"prefix":"10.1186","volume":"26","author":[{"given":"Tengbo","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"10153","key":"4690_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet (London England). 2018;392(10153):1147\u201359.","journal-title":"Lancet (London England)"},{"issue":"5","key":"4690_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s11596-020-2253-6","volume":"40","author":"Z Papadopoulos","year":"2020","unstructured":"Papadopoulos Z. Recent Developments in the Treatment of Wet Age-related Macular Degeneration. Curr Med Sci. 2020;40(5):851\u20137.","journal-title":"Curr Med Sci"},{"issue":"1","key":"4690_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12886-020-01390-4","volume":"20","author":"Q Wu","year":"2020","unstructured":"Wu Q, Chen X, Feng K, Liu Y, Zhang C, Zhao L. Evaluation of efficacy and recurrence for anti-vascular endothelial growth factor therapy in idiopathic choroidal neovascularization. BMC Ophthalmol. 2020;20(1):115.","journal-title":"BMC Ophthalmol"},{"key":"4690_CR4","doi-asserted-by":"crossref","unstructured":"Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018;2018:9640131.","DOI":"10.1155\/2018\/9640131"},{"issue":"1","key":"4690_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1167\/iovs.13-13034","volume":"55","author":"EW Schneider","year":"2014","unstructured":"Schneider EW, Mruthyunjaya P, Talwar N, Harris Nwanyanwu K, Nan B, Stein JD. Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade. Investig Ophthalmol Vis Sci. 2014;55(1):542\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"4690_CR6","doi-asserted-by":"publisher","first-page":"OCT14","DOI":"10.1167\/iovs.16-19969","volume":"57","author":"PJ Rosenfeld","year":"2016","unstructured":"Rosenfeld PJ. Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. Investig Ophthalmol Vis Sci. 2016;57(9):OCT14\u201326.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4690_CR7","doi-asserted-by":"publisher","first-page":"29619","DOI":"10.1038\/srep29619","volume":"6","author":"N Nagai","year":"2016","unstructured":"Nagai N, Suzuki M, Uchida A, Kurihara T, Kamoshita M, Minami S, Shinoda H, Tsubota K, Ozawa Y. Non-responsiveness to intravitreal aflibercept treatment in neovascular age-related macular degeneration: implications of serous pigment epithelial detachment. Sci Rep. 2016;6:29619.","journal-title":"Sci Rep"},{"issue":"14","key":"4690_CR8","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/s41433-023-02439-6","volume":"37","author":"PAH Nichani","year":"2023","unstructured":"Nichani PAH, Popovic MM, Dhoot AS, Pathak A, Muni RH, Kertes PJ. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye (Lond). 2023;37(14):2855\u201363.","journal-title":"Eye (Lond)"},{"issue":"8","key":"4690_CR9","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/IAE.0b013e31820d3d01","volume":"31","author":"HJ Shin","year":"2011","unstructured":"Shin HJ, Chung H, Kim HC. Association between foveal microstructure and visual outcome in age-related macular degeneration. Retina (Philadelphia Pa). 2011;31(8):1627\u201336.","journal-title":"Retina (Philadelphia Pa)"},{"key":"4690_CR10","doi-asserted-by":"crossref","unstructured":"Ying G-s, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF. Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2015;122(12).","DOI":"10.1016\/j.ophtha.2015.08.015"},{"key":"4690_CR11","doi-asserted-by":"crossref","unstructured":"Subhi Y, S\u00f8rensen TL. Neovascular age-related macular degeneration in the very old (\u2265\u200990 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol. 2017;2017:7194927.","DOI":"10.1155\/2017\/7194927"},{"issue":"9","key":"4690_CR12","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/IAE.0000000000002678","volume":"40","author":"H Lee","year":"2020","unstructured":"Lee H, Lee M, Kim MA, Chung H, Kim HC, ASSOCIATION OF TREATMENT RESPONSE WITH QUANTITATIVE CHANGES IN CHOROIDAL NEOVASCULARIZATION AND CHOROIDAL VESSEL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina (Philadelphia Pa). 2020;40(9):1704\u201318.","journal-title":"Retina (Philadelphia Pa)"},{"issue":"1","key":"4690_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1167\/iovs.13-12658","volume":"55","author":"T Asai","year":"2014","unstructured":"Asai T, Ikuno Y, Nishida K. Macular microstructures and prognostic factors in myopic subretinal hemorrhages. Investig Ophthalmol Vis Sci. 2014;55(1):226\u201332.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"4690_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.survophthal.2024.08.003","volume":"70","author":"JU Sheth","year":"2024","unstructured":"Sheth JU, Stewart MW, Narayanan R, Anantharaman G, Chandran K, Lai TYY, Chakravarthy U, Das T. Macular neovascularization. Surv Ophthalmol. 2024;70(4):653\u201375.","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"4690_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721\u201331.","journal-title":"Eye (Lond)"},{"issue":"10","key":"4690_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40266-015-0300-y","volume":"32","author":"A Garc\u00eda-Layana","year":"2015","unstructured":"Garc\u00eda-Layana A, Figueroa MS, Araiz J, Ruiz-Moreno JM, G\u00f3mez-Ulla F, Arias-Barquet L, Reiter N. Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept. Drugs Aging. 2015;32(10):797\u2013807.","journal-title":"Drugs Aging"},{"issue":"11","key":"4690_CR17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","volume":"121","author":"AC Ho","year":"2014","unstructured":"Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P. Twenty-four-month efficacy and safety of 0.5\u00a0mg or 2.0\u00a0mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181\u201392.","journal-title":"Ophthalmology"},{"issue":"6","key":"4690_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.ophtha.2015.02.031","volume":"122","author":"TA Ciulla","year":"2015","unstructured":"Ciulla TA, Ying G-S, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA. Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2015;122(6):1203\u201311.","journal-title":"Ophthalmology"},{"issue":"6","key":"4690_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.preteyeres.2007.07.004","volume":"26","author":"X He","year":"2007","unstructured":"He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R, Massaro-Giordano M, Dunaief JL. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26(6):649\u201373.","journal-title":"Prog Retin Eye Res"},{"key":"4690_CR20","unstructured":"Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL, et al. Outcomes of eyes with lesions composed of >\u200950% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology. 2015;122(2)."},{"issue":"14","key":"4690_CR21","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"4690_CR22","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1167\/iovs.15-16735","volume":"56","author":"F Coscas","year":"2015","unstructured":"Coscas F, Coscas G, Lupidi M, Dirani A, Srour M, Semoun O, Fran\u00e7ais C, Souied EH. Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. Investig Ophthalmol Vis Sci. 2015;56(6):4129\u201334.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"4690_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3341\/kjo.2014.28.5.386","volume":"28","author":"YH Kwon","year":"2014","unstructured":"Kwon YH, Lee DK, Kim HE, Kwon OW. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration. Korean J Ophthalmology: KJO. 2014;28(5):386\u201392.","journal-title":"Korean J Ophthalmology: KJO"},{"key":"4690_CR24","first-page":"518170","volume":"2013","author":"Y Mitamura","year":"2013","unstructured":"Mitamura Y, Mitamura-Aizawa S, Katome T, Naito T, Hagiwara A, Kumagai K, Yamamoto S. Photoreceptor impairment and restoration on optical coherence tomographic image. J Ophthalmol. 2013;2013:518170.","journal-title":"J Ophthalmol"},{"issue":"1","key":"4690_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1167\/iovs.09-3813","volume":"51","author":"FG Holz","year":"2010","unstructured":"Holz FG, Korobelnik J-F, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Investig Ophthalmol Vis Sci. 2010;51(1):405\u201312.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"4","key":"4690_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663\u201371.","journal-title":"Ophthalmology"},{"issue":"2","key":"4690_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","volume":"36","author":"BJ Fenner","year":"2021","unstructured":"Fenner BJ, Cheung CMG, Sim SS, Lee WK, Staurenghi G, Lai TYY, Ruamviboonsuk P, Kokame G, Yanagi Y, Teo KYC. Evolving treatment paradigms for PCV. Eye. 2021;36(2):257\u201365.","journal-title":"Eye"},{"issue":"12","key":"4690_CR28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1136\/bjophthalmol-2019-315338","volume":"104","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang J, Zhou Y, Wang W, Zhao J, Yu W, Zhang D, Ding D, Li X, Chen Y. Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. Br J Ophthalmol. 2020;104(12):1735\u201340.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"4690_CR29","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/bjo-2023-324713","volume":"108","author":"P Forte","year":"2024","unstructured":"Forte P, Fontana V, Muzio J, Di Cello L, Corazza P, Rosa R, Musetti D, Vagge A, Traverso CE, Nicol\u00f2 M. Predictors of 24-month onset of macular fibrosis in type 3 macular neovascularisation. Br J Ophthalmol. 2024;108(9):1240\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4690_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40942-025-00629-w","volume":"11","author":"J Cattaneo","year":"2025","unstructured":"Cattaneo J, Forte P, Forte G, Eandi CM. Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Na\u00efve and switch eyes. Int J Retina Vitreous. 2025;11(1):3.","journal-title":"Int J Retina Vitreous"},{"key":"4690_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ajo.2016.06.042","volume":"169","author":"A Carnevali","year":"2016","unstructured":"Carnevali A, Cicinelli MV, Capuano V, Corvi F, Mazzaferro A, Querques L, Scorcia V, Souied EH, Bandello F, Querques G. Optical Coherence Tomography Angiography: A Useful Tool for Diagnosis of Treatment-Na\u00efve Quiescent Choroidal Neovascularization. Am J Ophthalmol. 2016;169:189\u201398.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"4690_CR32","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1097\/IAE.0000000000003598","volume":"42","author":"R Sacconi","year":"2022","unstructured":"Sacconi R, Forte P, Capuano V, Miere A, Costanzo E, Tombolini B, Fantaguzzi F, Jung C, Parravano M, Varano M, et al. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHARACTERIZATION OF EVOLVING LESIONS IN FELLOW EYES OF EXUDATIVE TYPE 3 MACULAR NEOVASCULARIZATION PATIENTS. Retina. 2022;42(11):2075\u201382.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04690-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:17:24Z","timestamp":1775567844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04690-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4690"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04690-3","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective, non-randomized, non-comparative study was conducted following the guidelines of the Declaration of Helsinki. This study passed the ethical review of the Peking University Third Hospital Medical Science Research Ethics Committee (Approval No.IRB00006761-M2021613). The use of all prospective data in this study was approved with informed consent obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}